lung cancer Archives -

Transforming NSCLC standards of care

2nd NSCLC Drug Development Summit

https://pharmaphorum.com/events/2nd-nsclc-drug-development-summit/

Median Tech debuts AI-focused unit for cancer trial support

Phil Taylor digital, digital health, iBiopsy, imaging, Liver cancer, lung cancer, Median Technologies, Oncology 0 Comment

Medical imaging specialist Median Technologies has launched a new business unit that will provide decision-making tools – underpinned

Median Tech debuts AI-focused unit for cancer trial support

https://pharmaphorum.com/news/median-tech-debuts-ai-focused-unit-for-cancer-trial-support/

News/ News/ Oncology

Sugemalimab plus chemo boosts lung cancer survival, trial reveals

Joy Persaud cancer, clinical trials, lung cancer, pharma 0 Comment

Lung cancer drug sugemalimab has delivered positive results following a phase 3 trial. The GEMSTONE-302 study evaluated the

Sugemalimab plus chemo boosts lung cancer survival, trial reveals

https://pharmaphorum.com/news/sugemalimab-plus-chemo-boosts-lung-cancer-survival-trial-reveals/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ Oncology

Scotland is world’s first country to greenlight Tagrisso for NSCLC

Joy Persaud Astra Zeneca, lung cancer, NSCLC, Tagrisso 0 Comment

Scotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small

Scotland is world’s first country to greenlight Tagrisso for NSCLC

https://pharmaphorum.com/news/scotland-is-worlds-first-country-to-greenlight-tagrisso-for-nsclc/

News/ News/ Oncology

Opdivo and chemotherapy combo increases survival in lung cancer patients

Joy Persaud lung cancer, Opdivo 0 Comment

Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable

Opdivo and chemotherapy combo increases survival in lung cancer patients

https://pharmaphorum.com/news/opdivo-chemotherapy-combo-increases-survival-lung-cancer-patients/

News/ News/ Oncology

Strike two for Novartis’ lung cancer antibody canakinumab

Phil Taylor canakinumab, Immunology and inflammation, lung cancer, Novartis, Oncology 0 Comment

Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3

Strike two for Novartis’ lung cancer antibody canakinumab

https://pharmaphorum.com/news/strike-two-for-novartis-lung-cancer-antibody-canakinumab/

News/ News/ Oncology

Good news for Lilly as sintilimab hits the spot in lung cancer again

Phil Taylor Eli Lilly, immuno-oncology, Innovent, lung cancer, Oncology, sintilimab 0 Comment

Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent’s

Good news for Lilly as sintilimab hits the spot in lung cancer again

https://pharmaphorum.com/news/good-news-for-lilly-as-sintilimab-hits-the-spot-in-lung-cancer-again/

News/ News/ Oncology

Roche scores adjuvant lung cancer approval for Tecentriq

Phil Taylor adjuvant, immuno-oncology, Keytruda, lung cancer, Merck & Co, NSCLC, Oncology, regulatory approval, Roche, Tecentriq 0 Comment

Roche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC),

Roche scores adjuvant lung cancer approval for Tecentriq

https://pharmaphorum.com/news/roche-scores-early-adjuvant-lung-cancer-approval-for-tecentriq/

News/ News/ Oncology

NHS fast tracks access to Amgen’s just-approved KRAS cancer drug

Phil Taylor access, Amgen, KRAS, lung cancer, MHRA, NHS, Oncology, Project Orbis, sotorasib 0 Comment

Amgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement

NHS fast tracks access to Amgen’s just-approved KRAS cancer drug

https://pharmaphorum.com/news/nhs-fast-tracks-access-to-amgens-just-approved-kras-cancer-drug/

Trending

lung cancer

Login